Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus Nivolumab

Yusuke Yano(Osaka University of Pharmaceutical Sciences), Haruhito Azuma(Osaka University of Pharmaceutical Sciences), Yosuke Hirasawa(Cedars-Sinai Medical Center), Takuya Tsujino(Osaka University of Pharmaceutical Sciences), Atsuhiko Yoshizawa(Fujita Health University Hospital), Fumihiko Urabe(Jikei University School of Medicine), Kosuke Iwatani(Jikei University School of Medicine), Shogo Yamazaki(Osaka University of Pharmaceutical Sciences), Wataru Fukuokaya(Jikei University School of Medicine), Keita Nakamori(Osaka University of Pharmaceutical Sciences), Jun Miki(Jikei University School of Medicine), Keiichiro Mori(Jikei University School of Medicine), Kazuki Nishimura(Osaka University of Pharmaceutical Sciences), Takafumi Yanagisawa(Jikei University School of Medicine), Takahiro Adachi(Tokyo Medical University), Shunsuke Tsuduki(Jikei University School of Medicine), Shutaro Yamamoto, Yoshio Ohno(Tokyo Medical University), Teruo Inamoto(Hamamatsu University), Takeshi Hashimoto(Tokyo Medical University), Kazumasa Komura(Kawasaki Medical School), Ryoichi Shiroki(Fujita Health University), Satoshi Tokushige(Osaka University of Pharmaceutical Sciences), Takahiro Kimura(Jikei University School of Medicine), Takaya Ohno(Osaka University of Pharmaceutical Sciences), Taizo Uchimoto(Osaka University of Pharmaceutical Sciences), Kiyoshi Takahara(Osaka Medical and Pharmaceutical University)
Cancers
November 17, 2022
Cited by 21


Related Papers